The global hemophilia market is anticipated to grow with a significant CAGR of 6% during the forecast period. The hemophilia market growth is owing to the increasing demand for the prophylactic treatment of hemophilia. In addition to this, the increasing engagement of healthcare professionals, hemophilia treatment centers, as well as hemophilia societies to improve the care of hemophilia patients and their quality of life is also expected to drive the hemophilia market shares. Moreover, the continuous evolving treatment of hemophilia in recent years is also anticipated to propel the growth of the hemophilia market.

A full Report of Global Hemophilia Market at https://www.omrglobal.com/industry-reports/hemophilia-market

In general, the treatment of monogenetic bleeding disorders that is hemophilia A and B was done with the systemic protein replacement therapy. However, in recent years, a variety of diverse molecular medicines, ranging from antibody to gene to RNA therapy are transforming the treatment of hemophilia.
Moreover, the traditional replacement therapy used in the treatment of hemophilia required intravenous infusions of the factors for two to three times a week. While the new therapies in the market with extended half-life products are expected to reduce the frequency of injections. Additionally, multiple gene-editing techniques are under clinical or preclinical investigation for the treatment of hemophilia. Therefore, these new therapies and approaches that are being tested or launched are anticipated to considerably drive the size of the hemophilia industry during the forecast period.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hemophilia-market

In addition to this, several potential drugs can be used for the treatment of hemophilia are in their trials phase. These potential drugs are anticipated to provide new opportunities for the growth of the hemophilia market upon their market launch. For instance, Fitusiran an RNA-interference drug is in its Phase III trials. It is intended to be once a month injection that can both inhibits antithrombins and promotes the production of thrombin. Fitusiran can be used in both hemophilia A as well as hemophilia B treatment. Moreover, in January 2020 Sangamo Therapeutics has handed over the development of SB-525, (a gene therapy for hemophilia A), to Pfizer Inc. The company will now advance the therapy into Phase 3 clinical trials.

Global Hemophilia Market- Segmentation

By Type

• Hemophilia A
• Hemophilia B
• Others

By Therapy

• Replacement Therapy
• Gene Therapy
• Others

By Product Type

• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Others

Global Hemophilia Market- Segment by Region

North America

• The US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East Africa

Company Profiles

• Alnylam Pharmaceuticals, Inc
• Baxter International, Inc.
• Bayer AG
• BioMarin Pharmaceutical Inc.
• Biotest AG
• Catalyst Biosciences Inc.
• CSLLtd.
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd.
• GC Pharma (Green Cross Corp.)
• Genentech Inc. (HEMLIBRA)
• Grifols, S.A.
• Kedrion S.p.A
• Medexus Pharmaceuticals, Inc.
• Nektar Therapeutics
• Novo Nordisk A/S
• Octapharma AG
• Pfizer, Inc.
• Sanofi SA
• Spark Therapeutics, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Ltd.
:
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hemophilia-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404